NWL
48
4
TGNA
48
5
RRC
52
2
COF
48
3
GILD
55
5
EFX
43
3
VRSN
59
4
BAC
38
3
CTAS
36
8
HD
43
8
KR
50
5
CAT
47
3
GT
43
2
VFC
56
6
CMA
42
3
VTR
44
4
CMI
49
2
MMM
35
3
MA
60
5
CNP
59
17
NWL
48
4
TGNA
48
5
RRC
52
2
COF
48
3
GILD
55
5
EFX
43
3
VRSN
59
4
BAC
38
3
CTAS
36
8
HD
43
8
KR
50
5
CAT
47
3
GT
43
2
VFC
56
6
CMA
42
3
VTR
44
4
CMI
49
2
MMM
35
3
MA
60
5
CNP
59
17
Financhill
Back

CNS Pharmaceuticals Quote, Financials, Valuation and Earnings

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
36

CNSP
CNS Pharmaceuticals

Last Price:
$0.11
Seasonality Move:
-46.41%

7 Day Trial

ALL ACCESS PASS

$ 7

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.

CNS Pharmaceuticals Price Quote

$0.11
0.00 (0%)
(Updated: December 21, 2024 at 5:20 AM ET)

CNS Pharmaceuticals Key Stats

Sell
36
CNS Pharmaceuticals (CNSP) is a Sell
Day range:
$0.10 - $0.12
52-week range:
$0.10 - $70.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.9%
Volume:
4.6M
Avg. volume:
7.3M
1-year change:
-99.78%
Market cap:
$6.4M
Revenue:
$0
EPS:
$-70.72

How Much Does CNS Pharmaceuticals Make?

Data Unavailable

Is CNS Pharmaceuticals Growing As A Company?

Data Unavailable

CNS Pharmaceuticals Stock Price Performance

What Is CNS Pharmaceuticals 52-Week High & Low?

CNS Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy CNS Pharmaceuticals?

Data Unavailable

Is CNS Pharmaceuticals Cash Flow Positive?

Data Unavailable

CNS Pharmaceuticals Return On Invested Capital

Data Unavailable

CNS Pharmaceuticals Earnings Date & Stock Price

CNS Pharmaceuticals Competitors

  • Who Are CNS Pharmaceuticals's Competitors?
    Below is a list of companies who compete with CNS Pharmaceuticals or are related in some way:
    • Cellectar Biosciences Inc (CLRB)
    • Ligand Pharmaceuticals Inc (LGND)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Revance Therapeutics Inc (RVNC)
    • Zymeworks Inc (ZYME)

CNS Pharmaceuticals Dividend Yield

Data Unavailable

CNS Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable